On 2 February 2026, The United Laboratories International Holdings Limited (Stock Code: 3933) reported that its wholly owned subsidiary, The United Bio-Technology (Hengqin) Co., Ltd., gained approval from the China National Medical Products Administration (reference number CXHL2501306) for a clinical trial of UBT251 Injection targeting moderate to severe obstructive sleep apnea (OSA) with obesity.

UBT251 Injection is described as a multi-target peptide receptor agonist acting on the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors, designed to control blood glucose levels and curb weight gain. The company highlights that GLP-1-based weight-loss therapeutics may fill a significant unmet clinical need in addressing OSA.

Phase II clinical trials of UBT251 Injection for overweight or obesity, type 2 diabetes, metabolic-associated steatohepatitis (MASH), and chronic kidney disease (CKD) have already commenced in China. As the first chemically synthesized GLP-1R/GIPR/GCGR triple agonist new drug in the country, the product represents a key element in The United Laboratories’ research and development efforts.

Looking ahead, The United Laboratories International Holdings Limited intends to continue strengthening its pipeline of innovative biopharmaceuticals with the aim of enhancing its competitiveness and delivering added value to stakeholders. The announcement was dated 3 February 2026.